Bisphosphonates and bone fractures in long-term kidney transplant recipients

Transplantation

Volumn 86, Issue 2, 2008, Pages 231-237

  Conley, Emily ^a   Muth, Brenda ^a   Samaniego, Millie ^a   Lotfi, Mary ^a   Voss, Barbara ^b   Armbrust, Mike ^b   Pirsch, John ^b   Djamali, Arjang ^a,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c NONE   (United States)

Author keywords

Bisphosphonates; Dexa scan; Kidney transplantation; Osteopenia; Osteoporosis

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CYCLOSPORIN; ERGOCALCIFEROL; INTERLEUKIN 2 RECEPTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; VITAMIN D;

ADULT; ARTICLE; BONE DENSITOMETRY; BONE DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FEMUR NECK; FRACTURE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; PRIORITY JOURNAL; PROTEINURIA; RECEPTOR BLOCKING; RETROSPECTIVE STUDY; TREATMENT OUTCOME; BODY MASS; BONE; BONE DENSITY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; KIDNEY TRANSPLANTATION; METABOLIC BONE DISEASE; METHODOLOGY; MIDDLE AGED; OSTEOPOROSIS;

ADULT; BODY MASS INDEX; BONE AND BONES; BONE DENSITY; BONE DISEASES, METABOLIC; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OSTEOPOROSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 49249138330     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318176b40f     Document Type: Article

References (30)

1. Weisinger JR, Carlini RG, Rojas E, et al. Bone disease after renal transplantation. Clin J Am Soc Nephrol 2006; 1: 1300.
2. Cohen A, Sambrook P, Shane E. Management of bone loss after organ transplantation. J Bone Miner Res 2004; 19: 1919.
3. Cunningham J. Pathogenesis and prevention of bone loss in patients who have kidney disease and receive long-term immunosuppression. J Am Soc Nephrol 2007; 18: 223.
4. Cunningham J. Posttransplantation bone disease. Transplantation2005; 79: 629.
5. Jeffery JR, Leslie WD, Karpinski ME, et al. Prevalence and treatment of decreased bone density in renal transplant recipients: A randomized prospective trial of calcitriol versus alendronate. Transplantation2003; 76: 1498.
6. Mitterbauer C, SchwarzC, HaasM, et al. Effects of bisphosphonates on bone loss in the first year after renal transplantation - A meta-αnalysis of randomized controlled trials. Nephrol Dial Transplant 2006; 21: 2275.
7. Maalouf NM, Shane E. Osteoporosis after solid organ transplantation. J Clin Endocrinol Metab 2005; 90: 2456.
8. Grotz WH, Mundinger FA, Gugel B, et al. Bone fracture and osteoden-sitometry with dual energy x-ray absorptiometry in kidney transplant recipients. Transplantation1994; 58: 912.
9. Cunningham J. Bisphosphonates in the renal patient. Nephrol Dial Transplant 2007; 22: 1505.
10. Cruz DN, Brickel HM, Wysolmerski JJ,etal. Treatmentof osteoporosis and osteopenia in long-term renal transplant patients with alendro-nate. Am J Transplant2002; 2: 62.
11. Coco M, Glicklich D, Faugere MC, et al. Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003; 14: 2669.
12. Pascual J, Torrealba J, Myers J, et al. Collapsing focal segmental glo-merulosclerosis in a liver transplant recipient on alendronate. Osteoporos Int 2007; 18: 1435.
13. MunierA, GrasV,AndrejakM,etal. Zoledronic acid and renal toxicity: Data from French adverse effect reporting database.Ann Pharmacother 2005; 39: 1194.
14. Bilezikian JP. Osteonecrosis of the jaw - Do bisphosphonates pose a risk? N Engl J Med 2006; 355: 2278.
15. Graham DY. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci 2002; 47: 1665.
16. Strampel W, Emkey R, Civitelli R. Safety considerations with bisphos-phonates for the treatment of osteoporosis. Drug Saf 2007; 30: 755.
17. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535.
18. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333.
19. Grotz WH, Rump LC, Niessen A, et al. Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation1998; 66: 1004.
20. Giannini S, D'Angelo A, Carraro G, et al. Alendronate prevents further bone lossinrenal transplant recipients.J Bone Miner Res 2001; 16: 2111.
21. Djamali A, Kendziorski C, Brazy PC, et al. Disease progression and outcomes in chronic kidney disease and renal transplantation. Kidney Int 2003; 64: 1800.
22. Kukla A, Adulla M, Pascual J, et al. CKD stage-to-stage progression in native and transplant kidney disease. Nephrol Dial Transplant 2008; 23: 693.
23. DurieuxS, MercadalL,OrcelP,et al. Bone mineral density and fracture prevalence in long-term kidney graft recipients. Transplantation2002; 74: 496.
24. O'Shaughnessy EA, Dahl DC, Smith CL, et al. Risk factors for fractures in kidney transplantation. Transplantation2002; 74: 362.
25. Vautour LM, Melton LJ III, Clarke BL, et al. Long-term fracture risk following renal transplantation: A population-based study. Osteoporos Int 2004; 15: 160.
26. Hiramatsu K, Asaba Y, Takeshita S, et al. Overexpression of gamma-glutamyltransferase in transgenic mice accelerates bone resorption and causes osteoporosis. Endocrinology 2007; 148: 2708.
27. Niida S, Kawahara M, Ishizuka Y, et al. Gamma-glutamyltranspeptidase stimulates receptor activator of nuclear factor-kappaB ligand expression independentof its enzymatic activity and serves as a pathological bone-resorbing factor. J Biol Chem 2004; 279: 5752.
28. Asaba Y, Hiramatsu K, Matsui Y, et al. Urinary gamma-glutamyltransferase (GGT) as a potential marker of bone resorption. Bone 2006; 39: 1276.
29. Jorgensen L, Jenssen T, Ahmed L, et al. Albuminuria and risk of non-vertebral fractures. Arch Intern Med 2007; 167: 1379.
30. Smavatkul C, Pascual J, Desai AG, et al. Disease progression and outcomes in type 1 diabetic kidney transplant recipients based on posttransplantation CKD staging. Am J Kidney Dis 2007; 50: 631.